Loupi, E.Saliou, P.Blangy, H.Loeuille, D.Gillet, P.Debois, H.2011-09-292011-09-292011-09-292001https://infoscience.epfl.ch/handle/20.500.14299/71249WOS:000170184300010Objectives: Intravesical BCG therapy remains the first-line prophylactic treatment for recurrences of superficial bladder tumours. However necessary the safety, of this medicinal product, for which a potential risk of complications was demonstrated during development, needs to be evaluated.Bcgimmunotherapybladder cancer safetyCalmette-Guerin TherapyBladder-CancerComplicationsArthritisImmunotherapyInfectionCarcinomaPatientEvaluation of the safety of intravesical BCG therapy in France: analysis of serious adverse events notified over a three-year periodtext::journal::journal article::research article